The UK biotech, TC BioPharm (Holdings) Plc, has announced a research collaboration with the MD Anderson Cancer Center in the US to investigate how gamma delta T cells can be further mobilised to fight cancer. The Scotland-based company has already reported positive data from an early clinical trial of a gamma delta T cell product in patients with acute myeloid leukaemia (AML). As this trial continues, it will also be working with researchers at MD Anderson, which is part of the University of Texas, to better understand how gamma delta T cells behave in patients.
